Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004366 · ClinicalTrials.gov registry record · Phase 4
Linagliptin Inpatient Trial
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 295
- Enrollment target
NCT02004366 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 295 participants.
The verdict
NCT02004366, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 295 participants
- Enrollment target
Study Summary
This study is a prospective, randomized, open label trial to compare the safety and efficacy of linagliptin (an oral anti diabetic medication) given orally once daily to an insulin regimen of glargine once daily plus rapid-acting insulin before meals. Both of these treatment groups will be given corrective doses of rapid-acting insulin analogs (aspart, lispro or glulisine) before meals if their blood sugars are \> 140 mg/dl. The patients will be monitored for their blood sugars while the hospital. If patients are agreeable to participate in the discharge part of the study, the investigators will randomized them to a treatment group based on their admission HbA1c. The investigators will follow these patients for 3 months with phone calls and clinic visits, and will monitor their blood sugars. This is to compare the efficacy of linagliptin and our discharge treatment algorithm in controlling blood sugars as out patients.
Interventions
- DRUG Linagliptin
- DRUG Basal Bolus
- DRUG Linagliptin + 50% Glargine dose on discharge
- DRUG Linagliptin + 80% Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004366
The ClinicalTrials.gov registry entry for NCT02004366 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Linagliptin is the first listed.
NCT02004366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02004366 about?
NCT02004366 is a clinical study titled "Linagliptin Inpatient Trial". This study is a prospective, randomized, open label trial to compare the safety and efficacy of linagliptin (an oral anti diabetic medication) given orally once daily to an insulin regimen of glargine once daily plus rapid-acting insulin before meals. Both of these treatment groups will be given cor...
What is the current status of trial NCT02004366?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 295 participants. The study started on 2014-01. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02004366?
The interventions under investigation include: Linagliptin (DRUG), Basal Bolus (DRUG), Linagliptin + 50% Glargine dose on discharge (DRUG), Linagliptin + 80% Glargine (DRUG).
Who is sponsoring clinical trial NCT02004366?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.